The percentage of developmental malformations in 96 hpf zebrafish larvae (wild-type AB strain) exposed to different concentrations of N-[(3-chloro-4-methoxyphenyl)methylidene]-4-methylbenzenesulphonohydrazide. Concentrations: 3.39 mg/L = 10 µM; 16.94 mg/L = 50 µM; 33.88 mg/L = 100 µM; 84.70 mg/L = 250 µM. (A): Malformations: DD–developmental delay, YSE—yolk sac edema, TM—tail malformation. (B): Malformations: HM–head malformation, PE—pericardium edema, BS–bent spine.

The number of heart beats per minute of zebrafish larvae (wild-type AB strain) after 96-h exposure to control solutions and N-[(3-chloro-4-methoxyphenyl)methylidene]-4-methylbenzenesulphonohydrazide (SH) at the following concentrations: 1—16.94 mg/L (50 µM), 2—33.88 mg/L (100 µM), 3—84.70 mg/L (250 µM) (*** p < 0.001 vs. negative control; ∆∆∆ p < 0.001 vs. 1% DMSO).

The anti-angiogenic effect observed in Tg(fli1: EGFP) zebrafish embryos exposed 6 hpf (B,C), 12 hpf (E,F) and 24 hpf (H,I) to sorafenib at 1.16 mg/L (2.5 µM) (B,E,H) and 2.32 mg/L (5 µM) (C,F,I) vs respective negative controls (6 hpf-(A), 12 hpf-(D), 24 hpf-(G)) (24-h exposure; (A–C) 63× magnification, (D–I) 50× magnification).

The anti-angiogenic effect observed in Tg(fli1: EGFP) zebrafish embryos exposed 6 hpf (A–D) and 12 hpf (E,F) to N-[(3-chloro-4-methoxyphenyl)methylidene]-4-methylbenzenesulphonohydrazide at a concentration of 15.81 mg/L (46.67 µM) vs respective negative controls (6 hpf-(A), 12 hpf –(E)) (24-h exposure; ((A–D) 63× magnification, (E,F) 50× magnification).

Chemical structure of N-[(3-chloro-4-methoxyphenyl)methylidene]-4-methylbenzenesulphonohydrazide.